MD4596C1 - Pirolo[1,2,f][1,2,4] triazine utilizate pentru tratamentul infecţiilor cu virus sincitial respirator - Google Patents

Pirolo[1,2,f][1,2,4] triazine utilizate pentru tratamentul infecţiilor cu virus sincitial respirator

Info

Publication number
MD4596C1
MD4596C1 MDA20160063A MD20160063A MD4596C1 MD 4596 C1 MD4596 C1 MD 4596C1 MD A20160063 A MDA20160063 A MD A20160063A MD 20160063 A MD20160063 A MD 20160063A MD 4596 C1 MD4596 C1 MD 4596C1
Authority
MD
Moldova
Prior art keywords
pyrrolo
virus infections
respiratory syncytial
syncytial virus
treating respiratory
Prior art date
Application number
MDA20160063A
Other languages
English (en)
Russian (ru)
Other versions
MD4596B1 (ro
MD20160063A2 (ro
Inventor
Майкл О'Нил Хенрехен Кларк
Эдвард Доуэрффлер
Ричард Л. Макман
Дастин Сиджел
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4596(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20160063A2 publication Critical patent/MD20160063A2/ro
Publication of MD4596B1 publication Critical patent/MD4596B1/ro
Publication of MD4596C1 publication Critical patent/MD4596C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Invenţia se referă la compuşi de tetrahidrofuranil-pirolo[1,2-f][1,2,4]triazin-4-amină substituiţi, având formula (I) pentru tratamentul infecţiilor cu virus Pneumovirinae, inclusiv al infecţiilor cu virus respirator sincitial, precum şi la compoziţii, metode de utilizare şi compuşi intermediari pentru sinteza compuşilor de tetrahidrofuranil-pirolo[1,2-fl[1,2,4]triazin-4-amină.Revendicări: 54
MDA20160063A 2013-11-11 2014-11-06 Pirolo[1,2,f][1,2,4] triazine utilizate pentru tratamentul infecţiilor cu virus sincitial respirator MD4596C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902544P 2013-11-11 2013-11-11
PCT/US2014/064412 WO2015069939A1 (en) 2013-11-11 2014-11-06 Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections

Publications (3)

Publication Number Publication Date
MD20160063A2 MD20160063A2 (ro) 2016-11-30
MD4596B1 MD4596B1 (ro) 2018-10-31
MD4596C1 true MD4596C1 (ro) 2019-05-31

Family

ID=52003049

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160063A MD4596C1 (ro) 2013-11-11 2014-11-06 Pirolo[1,2,f][1,2,4] triazine utilizate pentru tratamentul infecţiilor cu virus sincitial respirator

Country Status (36)

Country Link
US (4) US9388208B2 (ro)
EP (3) EP4122932A1 (ro)
JP (7) JP6234571B2 (ro)
KR (4) KR102243724B1 (ro)
CN (3) CN105899216B (ro)
AP (1) AP2016009186A0 (ro)
AU (5) AU2014346665A1 (ro)
BR (1) BR112016010261B1 (ro)
CA (1) CA2928674C (ro)
CL (1) CL2016001120A1 (ro)
CR (1) CR20160220A (ro)
CU (1) CU20160065A7 (ro)
CY (1) CY1121948T1 (ro)
DK (2) DK3068405T3 (ro)
DO (1) DOP2016000107A (ro)
EA (2) EA039734B1 (ro)
ES (2) ES2743619T3 (ro)
GT (1) GT201600086A (ro)
HR (2) HRP20220920T1 (ro)
HU (2) HUE059683T2 (ro)
IL (1) IL245324B (ro)
LT (2) LT3068405T (ro)
MD (1) MD4596C1 (ro)
MX (2) MX2016006066A (ro)
MY (2) MY182986A (ro)
NZ (1) NZ719592A (ro)
PE (1) PE20160670A1 (ro)
PH (1) PH12016500867A1 (ro)
PL (2) PL3068405T3 (ro)
PT (2) PT3068405T (ro)
SG (1) SG11201603427XA (ro)
SI (2) SI3068405T1 (ro)
TR (1) TR201910961T4 (ro)
UA (1) UA119050C2 (ro)
WO (1) WO2015069939A1 (ro)
ZA (1) ZA201603123B (ro)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012003126A (es) 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
US20120027752A1 (en) 2010-07-22 2012-02-02 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
CN107073002B (zh) 2014-09-26 2019-10-15 里博科学有限责任公司 作为呼吸道合胞体病毒rna复制抑制剂的4’-乙烯基取代的核苷衍生物
TWI687432B (zh) * 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
BR112018005048B8 (pt) 2015-09-16 2021-03-23 Gilead Sciences Inc uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae
CA2998646C (en) * 2015-09-23 2021-05-18 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
TWI740910B (zh) 2016-03-09 2021-10-01 美商艾洛斯生物製藥公司 非環抗病毒劑
EP4331677A3 (en) 2017-03-14 2024-05-29 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US10836787B2 (en) 2017-05-01 2020-11-17 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
AU2018332540B2 (en) 2017-09-18 2023-10-05 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN109748921B (zh) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN108787177B (zh) * 2018-08-07 2024-03-15 中南大学 淤浆法制备黄原酸盐的方法及系统
US20220267362A1 (en) * 2019-05-14 2022-08-25 The Regents Of The University Of Michigan Methods for Glycosylation
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
JP7429799B2 (ja) * 2020-02-18 2024-02-08 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
TW202322824A (zh) * 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
TWI791193B (zh) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2，1-f][1，2，4]三嗪-4-胺的一种新合成方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
CN112778310A (zh) 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
KR20230018473A (ko) 2020-05-29 2023-02-07 길리애드 사이언시즈, 인코포레이티드 렘데시비르 치료 방법
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
CN115996928A (zh) 2020-06-24 2023-04-21 吉利德科学公司 1’-氰基核苷类似物及其用途
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
EP4192839A1 (en) 2020-08-06 2023-06-14 Richter Gedeon Nyrt. Remdesivir intermediates
AU2021331214B2 (en) 2020-08-27 2024-01-04 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN113880846B (zh) * 2020-12-31 2022-10-14 山东诚汇双达药业有限公司 一种7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的制备方法
EP4323362A1 (en) * 2021-04-16 2024-02-21 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
MX2024002116A (es) 2021-08-20 2024-03-06 Shionogi & Co Derivados de nucleosido y profarmacos de los mismos que tienen accion inhibidora del crecimiento viral.
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
AU2023227862A1 (en) 2022-03-03 2024-09-26 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20240199676A1 (en) 2022-03-03 2024-06-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (ro) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
DE69233690T2 (de) 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Abgabevorrichtung für nebelförmige Medikamente
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
EP1411954B1 (en) * 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
NZ578556A (en) 2007-01-12 2012-04-27 Biocryst Pharm Inc Antiviral nucleoside analogs
ES2393038T3 (es) * 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer
ATE515861T1 (de) 2007-07-25 2011-07-15 Nokia Siemens Networks Oy Verfahren zur adressierung von ethernetströmen mit strukturierter gpon-gem-port-id
ES2398684T3 (es) * 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
EP2480552B1 (en) 2009-09-21 2016-11-09 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
MX2012003126A (es) * 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
BR112013001267A2 (pt) 2010-07-19 2016-05-17 Gilead Sciences Inc métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
US20120027752A1 (en) * 2010-07-22 2012-02-02 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
PE20131165A1 (es) * 2010-09-20 2013-10-14 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
AU2011349844B2 (en) * 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
SG11201402826YA (en) * 2011-12-22 2014-12-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
JP6242378B2 (ja) * 2012-03-13 2017-12-06 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体
US10513534B2 (en) 2012-10-08 2019-12-24 Idenix Pharmaceuticals Llc 2′-chloro nucleoside analogs for HCV infection
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
EA201690978A1 (ru) 2016-09-30
HRP20220920T1 (hr) 2022-10-28
JP2020055855A (ja) 2020-04-09
NZ719592A (en) 2017-12-22
US10059716B2 (en) 2018-08-28
MY197933A (en) 2023-07-25
AU2017232039B2 (en) 2019-03-28
JP2024041986A (ja) 2024-03-27
JP6393380B2 (ja) 2018-09-19
EA039734B1 (ru) 2022-03-04
KR102113705B1 (ko) 2020-05-21
PE20160670A1 (es) 2016-07-10
US20180016280A1 (en) 2018-01-18
EP3505173A1 (en) 2019-07-03
PL3505173T3 (pl) 2022-10-17
CN114085243A (zh) 2022-02-25
AU2021201554A1 (en) 2021-04-01
KR20160074011A (ko) 2016-06-27
CL2016001120A1 (es) 2017-05-05
MX2016006066A (es) 2016-08-12
MY182986A (en) 2021-02-05
DK3068405T3 (da) 2019-07-29
IL245324B (en) 2018-08-30
CR20160220A (es) 2016-07-22
DK3505173T3 (da) 2022-08-22
GT201600086A (es) 2018-01-17
KR20200057103A (ko) 2020-05-25
DOP2016000107A (es) 2016-06-15
SI3505173T1 (sl) 2022-09-30
CA2928674C (en) 2018-10-02
AU2017232039C1 (en) 2019-07-25
CN110003215A (zh) 2019-07-12
EP3068405B1 (en) 2019-05-01
KR102355881B1 (ko) 2022-01-25
CN105899216A (zh) 2016-08-24
CN110003215B (zh) 2021-12-17
KR101864973B1 (ko) 2018-06-05
US10377761B2 (en) 2019-08-13
AP2016009186A0 (en) 2016-04-30
CY1121948T1 (el) 2020-10-14
JP2018070658A (ja) 2018-05-10
HRP20191303T1 (hr) 2019-10-18
KR20180059958A (ko) 2018-06-05
JP7247155B2 (ja) 2023-03-28
US9388208B2 (en) 2016-07-12
CA2928674A1 (en) 2015-05-14
HUE044960T2 (hu) 2019-12-30
US20190055253A1 (en) 2019-02-21
US9701682B2 (en) 2017-07-11
PT3068405T (pt) 2019-08-05
JP6234571B2 (ja) 2017-11-22
LT3505173T (lt) 2022-10-10
JP7054394B2 (ja) 2022-04-13
EP4122932A1 (en) 2023-01-25
AU2023202506A1 (en) 2023-05-11
MD4596B1 (ro) 2018-10-31
AU2019204381B2 (en) 2021-04-01
BR112016010261B1 (pt) 2022-02-08
JP2022088661A (ja) 2022-06-14
SI3068405T1 (sl) 2019-08-30
CU20160065A7 (es) 2016-09-30
HUE059683T2 (hu) 2022-12-28
US20170008897A1 (en) 2017-01-12
US20150133395A1 (en) 2015-05-14
ZA201603123B (en) 2019-08-28
IL245324A0 (en) 2016-06-30
PH12016500867A1 (en) 2016-06-20
EP3505173B1 (en) 2022-07-06
PL3068405T3 (pl) 2019-10-31
WO2015069939A1 (en) 2015-05-14
UA119050C2 (uk) 2019-04-25
MX2020010628A (es) 2020-10-22
MD20160063A2 (ro) 2016-11-30
KR102243724B1 (ko) 2021-04-23
EA201792639A1 (ru) 2018-09-28
JP2021046413A (ja) 2021-03-25
BR112016010261A2 (ro) 2017-08-08
AU2017232039A1 (en) 2017-10-12
ES2743619T3 (es) 2020-02-20
AU2021201554B2 (en) 2023-02-02
SG11201603427XA (en) 2016-05-30
EA029712B1 (ru) 2018-05-31
TR201910961T4 (tr) 2019-08-21
LT3068405T (lt) 2019-08-12
PT3505173T (pt) 2022-11-18
KR20210046833A (ko) 2021-04-28
ES2926155T3 (es) 2022-10-24
JP2017502925A (ja) 2017-01-26
CN105899216B (zh) 2019-03-05
CN114085243B (zh) 2024-04-26
EP3068405A1 (en) 2016-09-21
AU2019204381A1 (en) 2019-07-11
JP2018021051A (ja) 2018-02-08
AU2014346665A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
MD4596C1 (ro) Pirolo[1,2,f][1,2,4] triazine utilizate pentru tratamentul infecţiilor cu virus sincitial respirator
MX2019009687A (es) Procesos para la preparación de derivados de benzodiazepina.
NZ727996A (en) Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncytial virus infections
NZ728707A (en) 2’-chloro aminopyrimidinone and pyrimidine dione nucleosides
EA201791274A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
MX346602B (es) Compuestos beta-lactamicos sustituidos con amidina, su preparacion y uso como agentes antibacterianos.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
EA201300604A1 (ru) Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
EA201692063A1 (ru) Спиросоединения мочевины в качестве противовирусных соединений против rsv
MX2014001604A (es) Compuestos de antranilamida y sus usos como plaguicidas.
MX2014001510A (es) Compuestos de antranilamida y sus usos como plaguicidas.
IN2012DN06678A (ro)
MX2015000163A (es) Nuevos indazoles para el tratamiento y la profilaxis de la infeccion por virus sincitial respiratorio.
MX2014009933A (es) Diaminopirimidinas utiles como inhibidores del virus sincitial respiratorio humano (rsv).
MX371011B (es) Intermediarios y métodos para sintetizar derivados de calicheamicina.
MX2016001858A (es) Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio.
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.
PH12015502703A1 (en) Pharmaceutical compositions
NZ758580A (en) Pyrrolo[2,1-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
IN2013MU01219A (ro)
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees